The real-time PCR-based companion diagnostic test identifies patients eligible for treatment with Amgen's Vectibix (panitumumab).

The firm said that its overall revenues rose 2 percent year over year and 4 percent on an organic basis with a smaller increase in its life sciences revenues.

The first $25 million tranche was funded at close and used to retire Exagen's existing term debt facility with Innovatus Capital Partners.

NEW YORK — Digital pathology firm Gestalt Diagnostics said on Monday that it has raised $7.5 million through a Series A financing round. The round was led by Cowles Ventures, TVF Funds, Inland Imaging ...

The company said during a conference call following release of its Q1 2025 results that it purchases roughly 80 percent of ...

In one case a firm is alleged to have improperly billed the COVID-19 Uninsured Program while in the other a firm paid and received kickbacks for unnecessary genetic testing.

The company, also known as DRW, shared early data on its forthcoming multiplex qPCR-based platform and infectious disease ...

SSID Group said that the assets acquired in the deal will complement its gastric health portfolio and let it offer a broader range of tests to US labs.

The agency could continue to pursue more extensive LDT oversight by tightening control over items like RUO reagents and specimen collection devices.

NEW YORK – Impacts from China's volume-based procurement program and other healthcare pricing reforms led to flat Q1 diagnostics revenues year over year for Roche, company executives said Thursday.

A number of the Dutch firm's products have received certification under Europe's In Vitro Diagnostic Regulation recently.